Glenmede Trust’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Glenmede Trust’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-240	Closed	-$1K	–	2533
2020 Q3	$1K	Hold	240	–	–	﹤0.01%	2436
2020 Q2	$1K	Hold	240	–	–	﹤0.01%	2418
2020 Q1	$1K	Hold	240	–	–	﹤0.01%	2972
2019 Q4	$1K	Hold	240	–	–	﹤0.01%	2972
2019 Q3	$0	Hold	240	–	–	﹤0.01%	3173
2019 Q2	$1	Hold	240	–	–	﹤0.01%	3014
2019 Q1	$3	Hold	240	–	–	﹤0.01%	2783
2018 Q4	$2	Buy	+240	New	+$2.86K	﹤0.01%	2819
2018 Q2	–	Sell	-295	Closed	-$6K	–	2426
2018 Q1	$6K	Hold	295	–	–	﹤0.01%	2368
2017 Q4	$6K	Hold	295	–	–	﹤0.01%	2368
2017 Q3	$12K	Hold	295	–	–	﹤0.01%	2135
2017 Q2	$10K	Hold	295	–	–	﹤0.01%	2130
2017 Q1	$10K	Buy	+295	New	+$13K	﹤0.01%	2130

Other funds holding FPRX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Glenmede Trust's FPRX Position: Q4 2020 in Review

Glenmede Trust sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2020, closing a stake of 240 shares — an estimated $1K sold.

Glenmede Trust first reported a position in FPRX in Q1 2017 and held it in 13 quarters. The position peaked at $12K in Q3 2017. 125 funds tracked by Wall St. Rank hold FPRX as of Q4 2020.

Glenmede Trust reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 240 Five Prime Therapeutics, Inc. shares in Q4 2020, an estimated $1K.
Glenmede Trust first reported a position in Five Prime Therapeutics, Inc. in Q1 2017 and held it in 13 quarters.
Glenmede Trust's Five Prime Therapeutics, Inc. position peaked at $12K in Q3 2017.
125 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.